Abstract:The case presented describes the combined onset of heparin-induced thrombocytopenia II (HIT) and post-transfusion purpura (PTP) 5-10 days following exposure to heparin and blood transfusion during aortic dissection repair. On day 4 the platelet count decreased by 40% and D-dimers started to increase again. Despite a low clinical probability for HIT-II at this time (4T score of 3) serological testing was done the next day and yielded a negative test result. Following a transient rise after platelet transfusion another 40% decrease in platelet count occurred on day 8. To increase precision of the 4T score, screening ultrasonography was performed and identified a clinically unapparent jugular vein thrombosis. As this increased the 4T score to 6 points, serological testing was repeated and now showed the presence of HIT-II antibodies. Despite switching from heparin to argatroban the platelet count continued to decrease to <5×10(3)/µl. Conventional clotting tests showed a prolonged prothrombin time and severe hypofibrinogenemia. Because of the female sex, age >50 years, history of pregnancy and transfusion 8 days before, PTP was suspected. The alteration of the plasmatic coagulation, however, could not be explained by PTP. Therefore, disseminated intravascular coagulation (DIC) and interference of argatroban with conventional clotting tests were considered as alternative diagnoses. In order to differentiate between the two alternatives rotational thrombelastometry (ROTEM®) was performed and revealed an increased functional fibrinogen level without signs of hyperfibrinolysis. This argued for an interference of argatroban with the Clauss method of fibrinogen measurement and rendered DIC unlikely. Under suspicion of PTP, treatment with immunoglobulin was initiated and blood transfusions were avoided. Detection of PTP antibodies 1 day later confirmed the combined presence of PTP and HIT-II. As hyperfibrinogenemia compensated for the effects of thrombocytopenia on clot firmness in ROTEM®, anticoagulation with lepirudin was started at 9×10(3) platelets/µl only. The next day the platelet count increased to 32×10(3)/µl and clot firmness returned to normal. No thromboembolic complications and no relevant bleeding were observed. In summary, this case shows for the first time that HIT-II and PTP can occur in parallel in patients with simultaneous exposure to heparin and blood transfusions. Confounding effects of argatroban on conventional clotting tests may mimic DIC under these circumstances and make diagnosis difficult. Careful evaluation of the time-related magnitude in platelet decrease, patient history, course of D-dimers, screening ultrasonography and ROTEM® seem to be helpful to initiate early appropriate therapy before serological test results become available. In contrast to the Clauss method of fibrinogen measurement, assessment of clot firmness in ROTEM® is not influenced by argatroban. Moreover, ROTEM® reveals the compensatory effects of increased functional fibrinogen on clot firmness during severe thrombocytopenia as an important variable for anticoagulation therapy during thrombocytopenia with increased thromboembolic risk.

Acute Stent Thrombosis in an Immune Thrombocytopenic Purpura Patient: Striking the Balance Using Eltrombopag

Catastrophic anti-phospholipid syndrome with Libman-Sacks endocarditis following eltrombopag therapy for immune thrombocytopenic purpura: A case report

Eltrombopag as steroid sparing therapy for immune thrombocytopenic purpura in systemic lupus erythematosus

When Anticoagulation Backfires - Heparin-Induced Thrombocytopenia and Acute Stent Thrombosis following Endovascular Therapy for Deep Vein Thrombosis: A Case Report

Thrombocytopenia in acute coronary syndromes: etiologies and proposed management

Alternative Dosing of Eltrombopag for the Treatment of Chronic, Steroid-Refractory Immune Thrombocytopenia

Eltrombopag in Severe Immune Thrombocytopenia Secondary to Connective Tissue Disease: a Report of 17 Patients and Literature Review

Targeting Neutrophil Extracellular Trap Accumulation under Flow in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura

How complicated can be a case with immune thrombocytopenic purpura?: postsplenectomy arterial thrombosis

Refining the standard of care in immune thrombotic thrombocytopenic purpura

Transient Complete Recovery of Chronic Refractory Idiopathic Thrombocytopenic Purpura after Treatment with Monoclonal Antibody Targeting SARS-CoV-2 Spike Protein

Clopidogrel-induced refractory thrombotic thrombocytopenic purpura successfully treated with rituximab

Eptifibatide-Induced Profound Thrombocytopenia After Percutaneous Intervention for Acute Coronary Syndrome: A Challenging Clinical Scenario

Acute thrombosis of a mesenteric artery drug-eluting stent following clopidogrel cessation

Acute lower-extremity arterial thrombosis with immune thrombocytopenia

A nightmare of clopidogrel resistance in a resource-limited setting: case report of subacute stent thrombosis

The immune thrombocytopenia paradox: Should we be concerned about thrombosis in ITP?

[Management of complex thrombocytopenia with thrombelastometry : a case of simultaneous posttransfusion purpura and heparin-induced thrombocytopenia]

Left main stent thrombosis complicated by eptifibatide-induced acute thrombocytopenia

Primary Immune Thrombocytopenia: Novel Insights into Pathophysiology and Disease Management

ITP: a historical perspective